ArticleNature2018
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.
Erratum issued Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06611501 (Glycemic Regulation as Endometriosis Adjunct Treatment), which is not on this map. Cited by 439 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
439citing papers in PubMed, 4 pooled it
27.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06611501 phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation
Glycemic Regulation as Endometriosis Adjunct Treatment
Who cites it
439 citing papers in PubMed, 4 syntheses or guidelines pooled it, 689 citations in OpenAlex.
- The metabolic syndrome-cancer axis: global research trends and clinical landscapes.Frontiers in endocrinology · 2026Pooled it
- The effects of carbohydrate-restricted diets on 24-h mean blood glucose levels measured by continuous glucose monitoring in type 2 diabetes: a hypothesis-generating meta-analysis.Frontiers in nutrition · 2025Pooled it
- The crucial role and mechanism of insulin resistance in metabolic disease.Frontiers in endocrinology · 2023Pooled it
- Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.Frontiers in endocrinology · 2023Pooled it
- Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study.Nature communications · 2026Trial
- SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.Breast cancer research and treatment · 2024Trial
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance.The Journal of clinical investigation · 2026Review
- Managing capivasertib-induced hyperglycemia: a report of 3 cases.JCEM case reports · 2026Article
- Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation.Medical oncology (Northwood, London, England) · 2026Review
- Effects of refined carbohydrates on immune markers after weight loss on a very-low-carbohydrate diet: A randomized controlled feeding trial.Cell press blue · 2026Article
- The Ketogenic Diet as Adjunctive Strategy in Cancer Treatment-Therapeutic Benefits and Metabolic Risk Using Breast Cancer as an Example.Nutrients · 2026Review
- Commentary beyond the ATP site: Cryo-EM views of allosteric PI3KActa pharmaceutica Sinica. B · 2026Article
- Ketogenic Diet as an Adjuvant in Epithelial Cancers: Mechanisms, Model Systems, and Translational Opportunities.Cancers · 2026Review
- Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer.The Journal of biological chemistry · 2026Article
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- Article
- Continuous glucose monitoring-guided management of capivasertib-associated hyperglycemia: A case series of three patients.Journal of diabetes investigation · 2026Article
- Article
379 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on byThe sugar loop.2018
- Erratum issued
Authors and funding
18 authors at 5 institutions in 2 countries.
Benjamin D HopkinsMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Chantal PauliInstitute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Xing DuDepartment of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
Diana G WangMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Xiang LiWeill Cornell Graduate School of Medical Sciences, New York, NY, USA.
David WuMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Solomon C AmadiumeMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Marcus D GoncalvesMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Cindy HodakoskiMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Mark R LundquistMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Rohan BarejaMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Yan MaDepartment of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
Emily M HarrisDepartment of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
Andrea SbonerMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Himisha BeltranMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Mark A RubinEnglander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.
Siddhartha MukherjeeDepartment of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA. sm3252@cumc.columbia.edu.
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. lcantley@med.cornell.edu.
Cornell University · USWeill Cornell Medicine · USColumbia University Irving Medical Center · USNewYork–Presbyterian Hospital · USNew York Hospital Queens · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MRole of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MProject 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI ZIPFEL, WARREN R · 2016 to 2020
$10.2MThe Role of PI3K in Growth RegulationR01GM041890 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI CANTLEY, LEWIS C. · 1990 to 2016
$4.1MNCI NIH HHS P01 CA117969NCI NIH HHS P30 CA013696NCI NIH HHS R35 CA197588NCI NIH HHS U54 CA210184NIGMS NIH HHS R01 GM041890
Abstract
Mutations in PIK3CA, which encodes the p110α subunit of the insulin-activated phosphatidylinositol-3 kinase (PI3K), and loss of function mutations in PTEN, which encodes a phosphatase that degrades the phosphoinositide lipids generated by PI3K, are among the most frequent events in human cancers
Indexed as
Phosphoinositide-3 Kinase InhibitorsAnimalsBlood GlucoseCell ProliferationCell SurvivalDisease Models, AnimalFeedback, PhysiologicalInsulinMaleMiceMice, Inbred C57BLMice, NudeNeoplasmsProtein Kinase InhibitorsSignal TransductionTOR Serine-Threonine KinasesBlood GlucoseInsulinmTOR protein, mousePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06611501ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.